About TransMedics Group Inc
Ticker
info
TMDX
Trading on
info
NASDAQ
ISIN
info
US89377M1099
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
Dr. Waleed H. Hassanein M.D.
Headquarters
info
200 Minuteman Road, Andover, MA, United States, 01810
Employees
info
728
Website
info
transmedics.com
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$3.93B
P/E ratio
info
57.88
EPS
info
$1.99
Dividend Yield
info
0.00%
Beta
info
2.09
Forward P/E ratio
info
49.26
EBIDTA
info
$100M
Ex dividend date
info
-
Price & volume
Market cap
info
$3.93B
Average daily volume
info
1.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
57.88
Forward P/E
info
49.26
PEG ratio
info
-
Trailing P/E
info
57.88
Price to sales
info
7.39
Price to book
info
12.32
Earnings
EPS
info
$1.99
EPS estimate (current quarter)
info
$0.43
EPS estimate (next quarter)
info
$0.30
EBITDA
info
$100M
Revenues (TTM)
info
$531M
Revenues per share (TTM)
info
$15.78
Technicals
Beta
info
2.09
52-week High
info
$172.78
52-week Low
info
$55.00
50-day moving average
info
$121.21
200-day moving average
info
$92.49
Short ratio
info
6.69
Short %
info
38.66%
Management effectiveness
ROE (TTM)
info
28.21%
ROA (TTM)
info
5.80%
Profit margin
info
13.49%
Gross profit margin
info
$318M
Operating margin
info
23.24%
Growth
Quarterly earnings growth (YoY)
info
162.50%
Quarterly revenue growth (YoY)
info
37.70%
Share stats
Outstanding Shares
info
34.1M
Float
info
33M
Insiders %
info
3.01%
Institutions %
info
111.83%
Analyst Insights & forecasts
info

67% Buy

33% Hold

0% Sell

Based on information from 9 analysts.

Average price target

info
$142.29
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.12
$0.29
-58.62%
Q3 • 24Missed
$0.19
$0.22
-13.64%
Q4 • 24Missed
$0.70
$0.24
190.10%
Q1 • 25Beat
$0.92
$0.45
106.60%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$144M
$25.7M
17.89%
Q1 • 25
$157M
$34.9M
22.18%
Q2 • 25
9.64%
35.92%
23.97%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$838M
$571M
68.20%
Q1 • 25
$891M
$572M
64.28%
Q2 • 25
6.33%
0.21%
-5.75%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-2.9M
$-27M
$3M
$-29.9M
Q1 • 25
$91.6M
$-9.1M
$7.1M
$82.5M
Q2 • 25
-3,308.72%
-66.44%
134.11%
-376.10%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a TransMedics Group Inc share?
Collapse

TransMedics Group Inc shares are currently traded for undefined per share.

How many shares does TransMedics Group Inc have?
Collapse

TransMedics Group Inc currently has 34.1M shares.

Does TransMedics Group Inc pay dividends?
Collapse

No, TransMedics Group Inc doesn't pay dividends.

What is TransMedics Group Inc 52 week high?
Collapse

TransMedics Group Inc 52 week high is $172.78.

What is TransMedics Group Inc 52 week low?
Collapse

TransMedics Group Inc 52 week low is $55.00.

What is the 200-day moving average of TransMedics Group Inc?
Collapse

TransMedics Group Inc 200-day moving average is $92.49.

Who is TransMedics Group Inc CEO?
Collapse

The CEO of TransMedics Group Inc is Dr. Waleed H. Hassanein M.D..

How many employees TransMedics Group Inc has?
Collapse

TransMedics Group Inc has 728 employees.

What is the market cap of TransMedics Group Inc?
Collapse

The market cap of TransMedics Group Inc is $3.93B.

What is the P/E of TransMedics Group Inc?
Collapse

The current P/E of TransMedics Group Inc is 57.88.

What is the EPS of TransMedics Group Inc?
Collapse

The EPS of TransMedics Group Inc is $1.99.

What is the PEG Ratio of TransMedics Group Inc?
Collapse

The PEG Ratio of TransMedics Group Inc is null.

What do analysts say about TransMedics Group Inc?
Collapse

According to the analysts TransMedics Group Inc is considered a buy.